for people ages 23-75 (full criteria)
study started
estimated completion



A 38 week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. Approximately 240 adults (males and females) with growth hormone deficiency will be included. Randomization will occur in a 1:1:1 ratio (lonapegsomatropin : placebo : daily somatropin product). This is a global trial that will be conducted in, but not limited to, the United States, Europe, and Asia.

Official Title

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency


Growth Hormone Deficiency Endocrine System Diseases Hormone Deficiency Human Growth Hormone hGH rhGH GHD Adult Growth Hormone Deficiency Long Acting Growth Hormone Lonapegsomatropin Prodrug Growth Failure Growth Hormone Replacement Therapy Sustained Release Growth Hormone TransCon hGH Dwarfism, Pituitary Somatropin


You can join if…

Open to people ages 23-75

  1. Age between 23 and 75 years, inclusive, at screening.
  2. AGHD Diagnosis Criteria

For adult-onset AGHD: documented history of structural hypothalamic-pituitary disease, hypothalamic-pituitary surgery, cranial irradiation, 1-4 non-GH pituitary hormone deficiencies, a proven genetic cause of GHD, or traumatic brain injury (TBI).

  1. For all countries except Japan: Subjects must satisfy at least one of the following criteria:
  2. Insulin tolerance test: peak GH ≤5 ng/mL
  3. Glucagon stimulation test according to body mass index (BMI)
    1. BMI ≤30 kg/m2: peak GH ≤3 ng/mL
  4. ii. BMI >30 kg/m2: peak GH ≤1 ng/mL
  5. Three or four pituitary axis deficiencies (i.e., adrenal, thyroid, gonadal, and/or vasopressin; not including GH) with IGF-1 SDS ≤ -2.0 at screening
  6. Macimorelin test: peak GH ≤2.8 ng/mL
  7. Growth hormone releasing hormone (GHRH) + arginine test according to BMI:
    1. BMI <25 kg/m2, peak GH <11 ng/mL
  8. ii. BMI ≥25-≤30 kg/m2, peak GH <8 ng/mL
  9. iii. BMI >30 kg/m2, peak GH <4 ng/mL
  10. For Japan only: Subjects with adult onset AGHD and deficiency of one or more other pituitary hormones need to satisfy at least one of the following criteria, while subjects with isolated GHD and no evidence of intracranial structure disorder (structural hypothalamic-pituitary disease) or with adult onset AGHD without deficiency of other pituitary hormones need to satisfy at least 2 of the following criteria:
  11. Insulin tolerance test: peak GH ≤1.8 ng/mL
  12. Glucagon test: peak GH ≤1.8 ng/mL
  13. Growth Hormone Releasing Peptide-2 (GHRP-2) tolerance test: peak GH ≤9 ng/mL
  14. IGF-1 SDS ≤ -1.0 at screening as measured by central laboratory.
  15. hGH treatment naïve or no exposure to hGH therapy or GH secretagogue for at least 12 months prior to screening.
  16. For subjects on hormone replacement therapies for any hormone deficiencies other than GH (e.g., adrenal, thyroid, estrogen, testosterone) must be on adequate and stable doses for ≥6 weeks prior to and throughout screening.
  17. For subjects not on glucocorticoid replacement therapy, documentation of adequate adrenal function at screening defined.
  18. For males not on testosterone replacement therapy: morning (6:00 - 10:00AM) total testosterone within normal limits for age.
  19. On a stable diet and exercise regime at screening with no intention to modify diet or exercise pattern during the trial, i.e., no weight reduction program intended during the trial or within the last 90 days prior to or through screening.
  20. No plans to undergo bariatric surgery during the trial.
  21. . Normal fundoscopy at screening (without signs/symptoms of intracranial hypertension or diabetic retinopathy above stage 2 / moderate). For subjects with a diagnosis of diabetes mellitus at screening, this must be documented with a fundus photograph.
  22. . Able and willing to provide a written informed consent and authorization for protected health information (PHI) disclosure in accordance with Good Clinical Practice (GCP).

You CAN'T join if...

  1. Known Prader-Willi Syndrome and/or other genetic diseases that may have an impact on an endpoint.
  2. Diabetes mellitus at screening if any of the following criteria are met:
  3. Poorly controlled diabetes, defined as HbA1c >7.5% at screening.
  4. Diabetes mellitus (defined as HbA1c ≥6.5% and/or fasting plasma glucose ≥126 mg/dL and/or plasma glucose ≥200 mg/dL two hours after oral glucose tolerance test) diagnosed <26 weeks prior to screening
  5. Change in diabetes regimen (includes dose adjustment) within <90 days prior and throughout screening
  6. Use of any diabetes drugs other than metformin and/or DPP-4 inhibitors for a cumulative duration of greater than 4 weeks within 12 months prior to screening
  7. Diabetes-related complications at screening (i.e., nephropathy as judged by the investigator, neuropathy requiring pharmacological treatment, retinopathy stage 2 / moderate and above within 90 days prior to screening or during screening)
  8. Active malignant disease or history of malignancy. Exceptions to this exclusion criterion:
  9. Resection of in situ carcinoma of the cervix uteri
  10. Complete eradication of squamous cell or basal cell carcinoma of the skin
  11. Subjects with GHD attributed to treatment of intracranial malignant tumors or leukemia, provided that a recurrence-free survival period of at least 5 years prior to screening is documented in the subject's file based on a Magnetic Resonance Imaging (MRI) result
  12. Evidence of growth of pituitary adenoma or other benign intracranial tumor within the last 12 months before screening.
  13. Subjects with acromegaly without remission / with documented remission less than 24 months prior to screening.
  14. Subjects with Cushing's disease without remission / with documented remission less than 24 months prior to screening.
  15. Subjects with prior cranial irradiation or hypothalamic-pituitary surgery: the procedure took place less than 12 months prior to screening.
  16. eGFR <60 mL/min/1.73m2 determined based on Modification of Diet in Renal Disease (MDRD) equation.
  17. Hepatic transaminases (i.e., AST or ALT) >3 times the upper limit of normal.
  18. . Heart failure NYHA class 3 or greater (NYHA 1994).
  19. . QTcF ≥ 451 milliseconds on 12-lead ECG at screening.
  20. . Poorly controlled hypertension.
  21. . Cerebrovascular accident within 5 years prior to screening.
  22. . Anabolic steroids (other than gonadal steroid replacement therapy) or oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout screening.
  23. . Currently using or have used within 26 weeks prior to screening any weight-loss or appetite-suppressive medications.
  24. . Known history of hypersensitivity and/or idiosyncrasy to any of the test compounds (somatropin) or excipients employed in this trial.
  25. . Known history of neutralizing anti-hGH antibodies.
  26. . Inability to undergo scanning by DXA or a non-interpretable DXA scan at screening.
  27. . Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods
  28. . Male subjects must use a condom, or his female partner of childbearing potential must use an effective form of contraception as described above, from the beginning of screening to the last trial visit.
  29. . Known substance abuse or known (or previous) eating disorders, including anorexia nervosa, bulimia and severe gastrointestinal disease affecting normal eating (as judged by the investigator).
  30. . Any disease or condition that, in the judgement of the investigator, may make the subject unlikely to comply with the requirements of the trial or any condition that presents undue risk from the investigational product or procedures.
  31. . Participation in another interventional clinical trial involving an investigational compound within 26 weeks prior to screening or in parallel to this trial.


  • Ascendis Pharma Investigational Site accepting new patients
    Los Angeles California 90095 United States
  • Ascendis Pharma Investigational Site accepting new patients
    Fresno California 93720 United States


accepting new patients
Start Date
Completion Date
Ascendis Pharma Endocrinology Division A/S
Phase 3
Study Type
Last Updated